A molecular pharmacology study into the anti-inflammatory actions of Euphorbia hirta L. on the LPS-induced RAW 264.7 cells through selective iNOS protein inhibition

Journal of Natural Medicines

Volumn 64, Issue 3, 2010, Pages 330-335

  Shih, Mei Fen ^a   Cheng, Yih Dih ^b   Shen, Chia Rui ^c   Cherng, Jong Yuh ^d  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

b Amyrin; Euphorbia hirta L.; Inflammation; iNOS; NO specific inhibitor

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA AMYRIN; EUPHORBIA HIRTA EXTRACT; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PLANT EXTRACT; PROSTAGLANDIN E2; REAGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; COLORIMETRY; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUPHORBIA HIRTA; GENE EXPRESSION; INFLAMMATION; MACROPHAGE; MEDICINAL PLANT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUPHORBIA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MOLECULAR STRUCTURE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PLANT EXTRACTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953621522     PISSN: 13403443     EISSN: 18610293     Source Type: Journal    
DOI: 10.1007/s11418-010-0417-6     Document Type: Article

References (25)

1. Abramson SB (2008) Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 10(Suppl 2):S2
2. Lee MS, Tu YK, Chao CCK, Chen SC, Chen CY, Chan YS, Yeh WL, Ueng SWN (2005) Inhibition of nitric oxide can ameliorate apoptosis and modulate matrix protein gene expression in bacteria infected chondrocytes in vitro. J Orthop Res 23:440-445
3. Hesslinger C, Strub A, Boer R, Ulrich WR, Lehner MD, Braun C (2009) Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 37:886-891
4. Kim YM, Lee BS, Yi KY, Paik SG (1997) Upstream NF-kappaB site is required for the maximal expression of mouse inducible nitric oxide synthase gene in interferon-gamma plus lipopolysaccharide- induced RAW 264.7 macrophages. Biochem Biophys Res Commun 236:655-660
5. Xie QW, Whisnant R, Nathan C (1993) Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide: suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 177:1779-1784
6. Lanhers MC, Fleurentin J, Cabalion P, Rolland A, Dorfman P, Misslin R, Pelt JM (1990) Behavioural effects of Euphorbia hirta L.: sedative and anxiolytic properties. J Ethnopharmacol 29:189-198
7. Lanhers MC, Fleurentin J, Dorfman P, Mortier F, Pelt JM (1991) Analgesic, antipyretic and anti inflammatory properties of Euphorbia hirta. Planta Med 57:225-231
8. Youssouf MS, Kaiser P, Tahir M, Singh GD, Singh S, Sharma VK, Satti NK, Haque SE, Johri RK (2007) Anti-anaphylactic effect of Euphorbia hirta. Fitoterapia 78:535-539
9. Galvez J, Zarzuelo A, Crespo ME, Lorente MD, Ocete MA, Jiménez J (1993) Anti-diarrhoeic activity of Euphorbia hirta extract and isolation of an active flavanoid constituent. Planta Med 59:333-336
10. Hore SK, Ahuja V, Mehta G, Pardeep K, Pandey SK, Ahmad AH (2006) Effect of aqueous Euphorbia hirta leaf extract on gastrointestinal motility. Fitoterapia 77:35-38
11. Sudhakar M, Rao ChV, Rao PM, Raju DB, Venkateswarlu Y (2006) Antimicrobial activity of Caesalpinia pulcherrima, Euphorbia hirta and Asystasia gangeticum. Fitoterapia 77:378-380
12. Vijaya K, Ananthan S, Nalini R (1995) Antibacterial effect of theaflavin, polyphenon 60 (Camellia sinensis) and Euphorbia hirta on Shigella spp.-a cell culture study. J Ethnopharmacol 49:115-118
13. Johnson PB, Abdurahman EM, Tiam EA, Abdu-Aguye I, Hussaini IM (1999) Euphorbia hirta leaf extracts increase urine output and electrolytes in rats. J Ethnopharmacol 65:63-69
14. Singh GD, Kaiser P, Youssouf MS, Singh S, Khajuria A, Koul A, Bani S, Kapahi BK, Satti NK, Suri KA, Johri RK (2006) Inhibition of early and late phase allergic reactions by Euphorbia hirta L. Phytother Res 20:316-321
15. Gupta DR, Garg SK (1966) A chemical examination of Euphorbia hirta Linn. Bull Chem Soc Jpn 39:2524-2532
16. Leite DF, Echevarria-Lima J, Calixto JB, Rumjanek VM (2007) Multidrug resistance related protein (ABCC1) and its role on nitrite production by the murine macrophage cell line RAW 264.7. Biomed Pharmacother 73:665-674
17. Terra X, Valls J, Vitrac X, Mérrillon JM, Arola L, Ardèvol A, Bladé C, Fernandez-Larrea J, Pujadas G, Salvadó J, Blay M (2007) Grape-seed procyanidins act as antiinflammatory agents in endotoxin-stimulated RAW 264.7 macrophages by inhibiting NFkB signaling pathway. J Agric Food Chem 55:4357-4365
18. Chang YC, Li PC, Chen BC, Chang MS, Wang JL, Chiu WT, Lin CH (2006) Lipoteichoic acid-induced nitric oxide synthase expression in RAW 264.7 macrophages is mediated by cyclooxygenase- 2, prostaglandin E2, protein kinase A, p38 MAPK, and nuclear factor-kappaB pathways. Cell Signal 18:1235-1243
19. Clancy RM, Aminm AR, Abramsonm SB (1998) The role of nitric oxide in inflammation and immunity. Arthritis Rheum 41:1141-1151
20. Kroncke KD, Fehsel K, Kolb-Bachofen V (1998) Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 113:147-156
21. Szabo C, Thiemermann C (1995) Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol 34:113-153
22. MacMicking J, Xie QW, Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323-350
23. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD (2006) Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20:2468-2475
24. Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619-626
25. Kavanaugh A (2007) Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment. Data from randomized clinical trials. Bull NYU Hosp Jt Dis 65(Suppl 1):S16-S20